• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

FDA Grants Priority Review to Sevabertinib NDA in HER2+ Lung Cancer

by MM360 Staff | May 29, 2025 | Uncategorized

Source: CureToday articles The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung cancer. Read More

Personalizing Prostate Cancer Care With Genetic Testing, PARP Inhibitors

by MM360 Staff | May 29, 2025 | Uncategorized

Source: CureToday articles Dr. Kristen Scarpato explains the role of genetic testing in prostate cancer care, as well as its use in determining treatment with PARP inhibitors. Read More

Expanding Access to Screening May Help Prevent Esophageal Cancer

by MM360 Staff | May 28, 2025 | Uncategorized

Source: CureToday articles Minimally invasive screening methods offer a more accessible, cost-effective way to detect Barrett’s esophagus early and help prevent esophageal cancer. Read More

HT-KIT Shows Activity in Rare KIT-Driven Cancers, Preclinical Data Finds

by MM360 Staff | May 28, 2025 | Uncategorized

Source: CureToday articles Preclinical data has showing compelling findings for HT-KIT among patients with rare and aggressive KIT-driven cancers, including GIST and some leukemias. Read More

Rebuilding Resilience: Navigating Aging and Exercise After CLL

by MM360 Staff | May 28, 2025 | Uncategorized

Source: CureToday articles After running the Boston Marathon at 67, I faced new limits from aging and chronic lymphocytic leukemia — but I’ve found ways to stay strong and resilient. Read More

Phase 1/2 Trial Investigating ATR-04 for EGFRi-Related Rashes in Lung Cancer

by MM360 Staff | May 28, 2025 | Uncategorized

Source: CureToday articles ATR-04 therapy is being investigated in the phase 1/2 ATR04-484 clinical trial for the treatment of EGFR inhibitor-associated rashes in lung cancer. Read More
« Older Entries
Next Entries »

Recent Content

  • NLA: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders
  • Novel Agents, Promising Data: The Evolving Landscape of Oncology Care
  • Day 1: Top Takeaways From ASCO25
  • NLA 2025: Inclisiran With Standard Care Provides Rapid, Sustained Lowering of LDL-C in Patients With Recent Acute Coronary Syndrome
  • Rapid Developments to Enhance Patient Experience in GU Cancer
  • Proactive Dermatologic Care Reduces Symptom Severity and Boosts Quality of Life in NSCLC
  • ASCO 2025: Racial Disparities and Advanced Staging in Early-Onset Colorectal Cancer
  • Additive Antihistamines May Improve Metastatic Bladder Cancer Outcomes
  • FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease
  • The Healing Power of Teddy Bears for Adults With Cancer
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT